537 related articles for article (PubMed ID: 36168619)
1. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.
Panagi M; Pilavaki P; Constantinidou A; Stylianopoulos T
Theranostics; 2022; 12(14):6106-6129. PubMed ID: 36168619
[TBL] [Abstract][Full Text] [Related]
2. Role of Immunotherapy in Sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Bone and Soft Tissue Sarcomas.
Uehara T; Fujiwara T; Takeda K; Kunisada T; Ozaki T; Udono H
Biomed Res Int; 2015; 2015():820813. PubMed ID: 26167500
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma.
Miwa S; Nishida H; Tanzawa Y; Takeuchi A; Hayashi K; Yamamoto N; Mizukoshi E; Nakamoto Y; Kaneko S; Tsuchiya H
Cancer; 2017 May; 123(9):1576-1584. PubMed ID: 28241093
[TBL] [Abstract][Full Text] [Related]
5. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
Nathenson MJ; Conley AP; Sausville E
Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
[TBL] [Abstract][Full Text] [Related]
7. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
8. Sarcomas of Soft Tissue and Bone.
Ferrari A; Dirksen U; Bielack S
Prog Tumor Res; 2016; 43():128-41. PubMed ID: 27595362
[TBL] [Abstract][Full Text] [Related]
9. The Landscape of Immunotherapy for Retroperitoneal Sarcoma.
Gingrich AA; Nassif EF; Roland CL; Keung EZ
Curr Oncol; 2023 Feb; 30(2):2144-2158. PubMed ID: 36826126
[TBL] [Abstract][Full Text] [Related]
10. Local Control of Soft Tissue and Bone Sarcomas.
Crompton JG; Ogura K; Bernthal NM; Kawai A; Eilber FC
J Clin Oncol; 2018 Jan; 36(2):111-117. PubMed ID: 29220297
[TBL] [Abstract][Full Text] [Related]
11. Emerging trends in immunotherapy for pediatric sarcomas.
Dyson KA; Stover BD; Grippin A; Mendez-Gomez HR; Lagmay J; Mitchell DA; Sayour EJ
J Hematol Oncol; 2019 Jul; 12(1):78. PubMed ID: 31311607
[TBL] [Abstract][Full Text] [Related]
12. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
[TBL] [Abstract][Full Text] [Related]
13. Soft tissue and bone sarcomas.
Santoro A; Bonadonna G
Cancer Chemother Biol Response Modif; 1991; 12():603-13. PubMed ID: 1931458
[No Abstract] [Full Text] [Related]
14. Biology of Bone Sarcomas and New Therapeutic Developments.
Brown HK; Schiavone K; Gouin F; Heymann MF; Heymann D
Calcif Tissue Int; 2018 Feb; 102(2):174-195. PubMed ID: 29238848
[TBL] [Abstract][Full Text] [Related]
15. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
16. Sarcomas of soft tissue and bone.
Mazanet R; Antman KH
Cancer; 1991 Aug; 68(3):463-73. PubMed ID: 2065265
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients.
Takahashi R; Ishibashi Y; Hiraoka K; Matsueda S; Kawano K; Kawahara A; Kage M; Ohshima K; Yamanaka R; Shichijo S; Shirouzu K; Itoh K; Sasada T
Cancer Sci; 2013 Oct; 104(10):1285-94. PubMed ID: 23829867
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment of Ewing sarcoma.
Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
